You are here

  • Home
  • Online First
  • Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Pet…

Article info

Article menu
Short report
Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia

Authors

  • Elena Shipitsyna Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian Federation PubMed articlesGoogle scholar articles
  • Tatiana Khusnutdinova Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian FederationDepartment of Clinical Laboratory Diagnostics, St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation PubMed articlesGoogle scholar articles
  • Olga Budilovskaya Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian FederationDepartment of Clinical Laboratory Diagnostics, St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation PubMed articlesGoogle scholar articles
  • Elizaveta Shedko Laboratory of Molecular Diagnostics and Epidemiology of Reproductive Tract Infections, Central Research Institute of Epidemiology, Moscow, Russian Federation PubMed articlesGoogle scholar articles
  • Elena Goloveshkina Laboratory of Molecular Diagnostics and Epidemiology of Reproductive Tract Infections, Central Research Institute of Epidemiology, Moscow, Russian Federation PubMed articlesGoogle scholar articles
  • Guzel Khayrullina Group of Development and Implementation of New Technologies and Products, Central Research Institute of Epidemiology, Moscow, Russian Federation PubMed articlesGoogle scholar articles
  • Anna Krysanova Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian FederationDepartment of Clinical Laboratory Diagnostics, St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation PubMed articlesGoogle scholar articles
  • Kira Shalepo Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian FederationDepartment of Clinical Laboratory Diagnostics, St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation PubMed articlesGoogle scholar articles
  • Alevtina Savicheva Department of Medical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russian FederationDepartment of Clinical Laboratory Diagnostics, St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation PubMed articlesGoogle scholar articles
  • Magnus Unemo WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Orebro universitet, Orebro, SwedenInstitute for Global Health, University College London, London, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Magnus Unemo, Department of Laboratory Medicine, Orebro universitet, SE-701 85 Orebro, Sweden; magnus.unemo{at}orebroll.se
View Full Text

Citation

Shipitsyna E, Khusnutdinova T, Budilovskaya O, et al
Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistance-associated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia
Sexually Transmitted Infections Published Online First: 16 June 2022. doi: 10.1136/sextrans-2021-055249

Publication history

  • Received August 9, 2021
  • Accepted May 1, 2022
  • First published June 16, 2022.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.